Seeking Alpha

Navidea Biopharmaceuticals (NAVB +1.9%) gains after Burrill Institutional Research initiated the...

Navidea Biopharmaceuticals (NAVB +1.9%) gains after Burrill Institutional Research initiated the shares with a Market Outperform on valuation and a price target of $5 a share. The firm says the stock represents an undervalued opportunity with multiple near-term drivers that are likely to create shareholder value in 2013. Separately, Aegis Capital starts the stock with a Hold rating and a $3.00 price target.
Comments (1)
  • adnen
    , contributor
    Comment (1) | Send Message
     
    lets go......stop 6,5 ??
    22 Jan 2013, 02:34 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector